Eventide Asset Management TMDX Position
Active3-Fund ConvergenceEventide Asset Management increased their position in TransMedics Group, Inc. (TMDX) in Q4 2025, holding $66.7M worth of shares across 548,267 shares.
The position was first reported in Q2 2023 and has been tracked across 11 quarterly 13F filings.
TMDX is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 41.5% of float with 9.0 days to cover, indicating significant bearish positioning against Eventide's long thesis.
About TransMedics Group, Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Full company profile →Short Interest
41.5%
9.0 days to cover
Eventide Asset Management TMDX Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Increased | 548,267 | +971 | $66.7M |
| Q3 2025 | Decreased | 547,296 | -59 | $61.4M |
| Q2 2025 | Decreased | 547,355 | -130,626 | $73.3M |
| Q1 2025 | Increased | 677,981 | +279 | $45.6M |
| Q4 2024 | Decreased | 677,702 | -12,930 | $42.2M |
| Q3 2024 | Decreased | 690,632 | -454,798 | $108.4M |
| Q2 2024 | Decreased | 1,145,430 | -24,465 | $172.5M |
| Q1 2024 | Increased | 1,169,895 | +175,655 | $86.5M |
| Q4 2023 | Increased | 994,240 | +68,884 | $78.5M |
| Q3 2023 | Increased | 925,356 | +857,895 | $50.7M |
| Q2 2023 | New | 67,461 | +67,461 | $5.7M |
Frequently Asked Questions
Does Eventide Asset Management own TMDX?
Yes. As of Q4 2025, Eventide Asset Management holds 548,267 shares of TransMedics Group, Inc. (TMDX) valued at $66.7M. This data comes from their SEC 13F filing.
How many hedge funds own TMDX?
3 specialist biotech hedge funds currently hold TMDX, including Driehaus Capital, Deerfield Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Eventide Asset Management first buy TMDX?
Eventide Asset Management's position in TMDX was first reported in Q2 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Eventide Asset Management's TMDX position increasing or decreasing?
Eventide Asset Management increased their TMDX position in the most recent quarter, adding 971 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
TMDXCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Eventide Asset ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →